These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 20851601)

  • 1. Discovery of N-benzyl-2-[(4S)-4-(1H-indol-3-ylmethyl)-5-oxo-1-phenyl-4,5-dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-6-yl]-N-isopropylacetamide, an orally active, gut-selective CCK1 receptor agonist for the potential treatment of obesity.
    Elliott RL; Cameron KO; Chin JE; Bartlett JA; Beretta EE; Chen Y; Jardine Pda S; Dubins JS; Gillaspy ML; Hargrove DM; Kalgutkar AS; LaFlamme JA; Lame ME; Martin KA; Maurer TS; Nardone NA; Oliver RM; Scott DO; Sun D; Swick AG; Trebino CE; Zhang Y
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6797-801. PubMed ID: 20851601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-Substituted piperazine-derived imidazole carboxamides as potent and selective CCK1R agonists for the treatment of obesity.
    Berger R; Zhu C; Hansen AR; Harper B; Chen Z; Holt TG; Hubert J; Lee SJ; Pan J; Qian S; Reitman ML; Strack AM; Weingarth DT; Wolff M; Macneil DJ; Weber AE; Edmondson SD
    Bioorg Med Chem Lett; 2008 Sep; 18(17):4833-7. PubMed ID: 18684621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists.
    Henke BR; Aquino CJ; Birkemo LS; Croom DK; Dougherty RW; Ervin GN; Grizzle MK; Hirst GC; James MK; Johnson MF; Queen KL; Sherrill RG; Sugg EE; Suh EM; Szewczyk JW; Unwalla RJ; Yingling J; Willson TM
    J Med Chem; 1997 Aug; 40(17):2706-25. PubMed ID: 9276016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. II. In vivo pharmacological characterization.
    Bignon E; Alonso R; Arnone M; Boigegrain R; Brodin R; Gueudet C; Héaulme M; Keane P; Landi M; Molimard JC; Olliero D; Poncelet M; Seban E; Simiand J; Soubrié P; Pascal M; Maffrand JP; Le Fur G
    J Pharmacol Exp Ther; 1999 May; 289(2):752-61. PubMed ID: 10215649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of N-[(4R)-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-2,2-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]pyridin-4-yl]-5-methyl-1H-pyrazole-3-carboxamide (MK-5596) as a novel cannabinoid-1 receptor (CB1R) inverse agonist for the treatment of obesity.
    Yan L; Huo P; Debenham JS; Madsen-Duggan CB; Lao J; Chen RZ; Xiao JC; Shen CP; Stribling DS; Shearman LP; Strack AM; Tsou N; Ball RG; Wang J; Tong X; Bateman TJ; Reddy VB; Fong TM; Hale JJ
    J Med Chem; 2010 May; 53(10):4028-37. PubMed ID: 20423086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.
    Smith BM; Smith JM; Tsai JH; Schultz JA; Gilson CA; Estrada SA; Chen RR; Park DM; Prieto EB; Gallardo CS; Sengupta D; Dosa PI; Covel JA; Ren A; Webb RR; Beeley NR; Martin M; Morgan M; Espitia S; Saldana HR; Bjenning C; Whelan KT; Grottick AJ; Menzaghi F; Thomsen WJ
    J Med Chem; 2008 Jan; 51(2):305-13. PubMed ID: 18095642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partial agonism, neutral antagonism, and inverse agonism at the human wild-type and constitutively active cholecystokinin-2 receptors.
    Foucaud M; Tikhonova IG; Langer I; Escrieut C; Dufresne M; Seva C; Maigret B; Fourmy D
    Mol Pharmacol; 2006 Mar; 69(3):680-90. PubMed ID: 16293711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity (II): Optimization of the C3 amino substituent.
    Hirst GC; Aquino C; Birkemo L; Croom DK; Dezube M; Dougherty RW; Ervin GN; Grizzle MK; Henke B; James MK; Johnson MF; Momtahen T; Queen KL; Sherrill RG; Szewczyk J; Willson TM; Sugg EE
    J Med Chem; 1996 Dec; 39(26):5236-45. PubMed ID: 8978852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. YM022 [(R)-1-[2,3-dihydro-1-(2'-methylphenacyl)-2-oxo-5-phenyl- 1H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea], a potent and selective gastrin/cholecystokinin-B receptor antagonist, prevents gastric and duodenal lesions in rats.
    Nishida A; Takinami Y; Yuki H; Kobayashi A; Akuzawa S; Kamato T; Ito H; Yamano M; Nagakura Y; Miyata K
    J Pharmacol Exp Ther; 1994 Sep; 270(3):1256-61. PubMed ID: 7932178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A concise synthesis of 1,4-dihydro-[1,4]diazepine-5,7-dione, a novel 7-TM receptor ligand core structure with melanocortin receptor agonist activity.
    Szewczyk JR; Laudeman CP; Sammond DM; Villeneuve M; Minick DJ; Grizzle MK; Daniels AJ; Andrews JL; Ignar DM
    Bioorg Med Chem; 2010 Mar; 18(5):1822-33. PubMed ID: 20172734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of imidazole carboxamides as potent and selective CCK1R agonists.
    Zhu C; Hansen AR; Bateman T; Chen Z; Holt TG; Hubert JA; Karanam BV; Lee SJ; Pan J; Qian S; Reddy VB; Reitman ML; Strack AM; Tong V; Weingarth DT; Wolff MS; MacNeil DJ; Weber AE; Duffy JL; Edmondson SD
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4393-6. PubMed ID: 18614364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
    Shearman LP; Stribling DS; Camacho RE; Rosko KM; Wang J; Tong S; Feng Y; Marsh DJ; Yu H; Guan X; Spann SK; Macneil DJ; Fong TM; Metzger JM; Goulet MT; Hagmann WK; Plummer CW; Finke PE; Mills SG; Shah SK; Truong Q; Van der Ploeg LH; Macintyre DE; Strack AM
    Eur J Pharmacol; 2008 Jan; 579(1-3):215-24. PubMed ID: 18021763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of pyridone-containing imidazolines as potent and selective inhibitors of neuropeptide Y Y5 receptor.
    Ando M; Sato N; Nagase T; Nagai K; Ishikawa S; Takahashi H; Ohtake N; Ito J; Hirayama M; Mitobe Y; Iwaasa H; Gomori A; Matsushita H; Tadano K; Fujino N; Tanaka S; Ohe T; Ishihara A; Kanatani A; Fukami T
    Bioorg Med Chem; 2009 Aug; 17(16):6106-22. PubMed ID: 19616955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of 1-(2,4-dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophen-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide as a potential peripheral cannabinoid-1 receptor inverse agonist.
    Hung MS; Chang CP; Li TC; Yeh TK; Song JS; Lin Y; Wu CH; Kuo PC; Amancha PK; Wong YC; Hsiao WC; Chao YS; Shia KS
    ChemMedChem; 2010 Sep; 5(9):1439-43. PubMed ID: 20652930
    [No Abstract]   [Full Text] [Related]  

  • 15. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
    Fong TM; Guan XM; Marsh DJ; Shen CP; Stribling DS; Rosko KM; Lao J; Yu H; Feng Y; Xiao JC; Van der Ploeg LH; Goulet MT; Hagmann WK; Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Francis B; Strack AM; MacIntyre DE; Shearman LP
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1013-22. PubMed ID: 17327489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The discovery of taranabant, a selective cannabinoid-1 receptor inverse agonist for the treatment of obesity.
    Hagmann WK
    Arch Pharm (Weinheim); 2008 Jul; 341(7):405-11. PubMed ID: 18574849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of N-[(1S,2S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity.
    Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Fong TM; Shen CP; Lao J; Xiao JC; Shearman LP; Stribling DS; Rosko K; Strack A; Marsh DJ; Feng Y; Kumar S; Samuel K; Yin W; Van der Ploeg LH; Goulet MT; Hagmann WK
    J Med Chem; 2006 Dec; 49(26):7584-7. PubMed ID: 17181138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger".
    Aquino CJ; Armour DR; Berman JM; Birkemo LS; Carr RA; Croom DK; Dezube M; Dougherty RW; Ervin GN; Grizzle MK; Head JE; Hirst GC; James MK; Johnson MF; Miller LJ; Queen KL; Rimele TJ; Smith DN; Sugg EE
    J Med Chem; 1996 Jan; 39(2):562-9. PubMed ID: 8558528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of 2-(4-benzyloxyphenyl)-N- [1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-6-yl]acetamide, an orally efficacious melanin-concentrating hormone receptor 1 antagonist for the treatment of obesity.
    Souers AJ; Gao J; Brune M; Bush E; Wodka D; Vasudevan A; Judd AS; Mulhern M; Brodjian S; Dayton B; Shapiro R; Hernandez LE; Marsh KC; Sham HL; Collins CA; Kym PR
    J Med Chem; 2005 Mar; 48(5):1318-21. PubMed ID: 15743174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of N-(3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-1H-indole-carboxamides as cholecystokinin antagonists.
    Lattmann E; Singh H; Boonprakob Y; Lattmann P; Sattayasai J
    J Pharm Pharmacol; 2006 Mar; 58(3):393-401. PubMed ID: 16536908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.